Σ R A T O S provides a physics‑based simulation platform that creates high‑resolution, human‑specific models of neural circuits and molecular pathways for CNS drug discovery. The tool enables pharmaceutical R&D teams to run in silico target validation, PK/PD analysis, and off‑target scenario testing, reducing reliance on animal models and accelerating candidate prioritization.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery for central nervous system (CNS) disorders relies heavily on animal models and limited in vitro assays, which often fail to predict human responses, leading to high failure rates and costly development cycles.
Solution
Σ R A T O S creates computational, ground‑truth world models of human biology that simulate CNS physiology and pathology at molecular and cellular resolution. These models enable pharmaceutical researchers to perform in silico target validation and mechanism‑of‑action studies, reducing dependence on animal experiments. By providing quantitative predictions of drug effects in a human-relevant context, the platform helps prioritize candidates, streamline preclinical workflows, and accelerate the design of effective CNS therapeutics.
Target Audience
Primary users are pharmaceutical R&D teams and biotech companies focused on CNS drug discovery, including medicinal chemists, pharmacologists, and translational scientists.
Features
- High‑fidelity, physics‑based simulations of human neural circuits and molecular pathways
- Integrated pharmacokinetic/pharmacodynamic (PK/PD) modeling for CNS drug distribution and activity
- Scenario testing for target engagement, off‑target effects, and disease progression
- Data export tools compatible with common drug discovery pipelines and analytics platforms
- Continuous model refinement using publicly available human omics and clinical datasets